Bristol Myers Squibb gets EMA Committee positive opinion for Reblozyl for adults with Transfusion-Dependent Anemia due to Low-to Intermediate-Risk Myelodysplastic Syndromes Ruchika Sharma25 Feb 2024 3:30 PM ISTPrinceton: Bristol Myers Squibb has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb, Immunocore Holdings ink pact to evaluate IMC-F106C, nivolumab combo in registrational Phase 3 first-line advanced cutaneous melanoma trial Ruchika Sharma25 Feb 2024 2:00 PM ISTOxfordshire: Immunocore Holdings plc, a commercial-stage biotechnology company has announced that it has entered into a clinical trial...
USFDA accepts for priority review Bristol Myers Squibb application for Krazati, cetuximab combo for colorectal cancer Ruchika Sharma22 Feb 2024 1:30 PM ISTNew York: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental...
Bristol Myers Squibb application for Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors accepted by USFDA for priority review Ruchika Sharma15 Feb 2024 11:13 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug...
Bristol Myers Squibb concludes acquisition of Mirati Therapeutics Ruchika Sharma26 Jan 2024 12:15 PM ISTThe transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb's non-GAAP earnings per share by...
Bristol Myers Squibb Repotrectinib application to treat cancer validated by EMA Ruchika Sharma4 Jan 2024 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its marketing authorization application...
Bristol Myers Squibb to acquire RayzeBio for USD 4.1 billion Ruchika Sharma28 Dec 2023 1:30 PM ISTPrinceton: Bristol Myers Squibb and RayzeBio, Inc. have announced a definitive merger agreement under which Bristol Myers Squibb will acquire...
Bristol Myers Squibb to acquire Karuna Therapeutics for USD 14 billion Ruchika Sharma25 Dec 2023 2:30 PM ISTPrinceton: Bristol Myers Squibb and Karuna Therapeutics, Inc. have announced that they have entered into a definitive merger agreement under...
Bristol Myers Squibb to discontinue trial for colorectal cancer treatment Ruchika Sharma17 Dec 2023 2:45 PM ISTPrinceton: Bristol Myers Squibb has announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and...
Bristol Myers Squibb, SystImmune collaborate for development, commercialization of BL-B01D1 Ruchika Sharma12 Dec 2023 12:30 PM ISTPrinceton: SystImmune, a clinical-stage biopharmaceutical company, and Bristol Myers Squibb have announced an exclusive license and collaboration...
Bristol Myers Squibb Abecma approved for use in earlier lines of therapy for patients with relapsed or refractory Multiple Myeloma in Japan Ruchika Sharma7 Dec 2023 4:30 PM ISTTokyo: Bristol-Myers Squibb K.K. has announced that the company has received manufacturing and marketing approval of the supplemental New Drug...
USFDA accepts for priority review Bristol Myers Squibb application for Opdivo plus Cisplatin-Based Chemotherapy for urothelial carcinoma Ruchika Sharma7 Dec 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License...
